AR121066A1 - Mutante de fimh, composiciones que lo contienen y uso del mismo - Google Patents

Mutante de fimh, composiciones que lo contienen y uso del mismo

Info

Publication number
AR121066A1
AR121066A1 ARP210100099A ARP210100099A AR121066A1 AR 121066 A1 AR121066 A1 AR 121066A1 AR P210100099 A ARP210100099 A AR P210100099A AR P210100099 A ARP210100099 A AR P210100099A AR 121066 A1 AR121066 A1 AR 121066A1
Authority
AR
Argentina
Prior art keywords
same
compositions containing
fimh
polypeptides
mutant
Prior art date
Application number
ARP210100099A
Other languages
English (en)
Inventor
Jan Grijpstra
Eveline Marleen Weerdenburg
Jeroen Geurtsen
Kellen Cristhina Fae
Louris Jakob Feitsma
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AR121066A1 publication Critical patent/AR121066A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen polipéptidos que comprenden un dominio lectina de FimH que comprende una mutación de aminoácido que hace que el dominio lectina de FimH esté en la configuración de afinidad baja por la manosa. Se describen además composiciones farmacéuticas que comprenden tales polipéptidos y métodos de estimulación de una respuesta inmunitaria en un sujeto que lo necesita mediante la administración del polipéptido.
ARP210100099A 2020-01-16 2021-01-15 Mutante de fimh, composiciones que lo contienen y uso del mismo AR121066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20152217 2020-01-16

Publications (1)

Publication Number Publication Date
AR121066A1 true AR121066A1 (es) 2022-04-13

Family

ID=69174406

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100099A AR121066A1 (es) 2020-01-16 2021-01-15 Mutante de fimh, composiciones que lo contienen y uso del mismo

Country Status (13)

Country Link
US (2) US11421003B2 (es)
EP (1) EP4090363A1 (es)
JP (2) JP7485771B2 (es)
KR (1) KR20220128372A (es)
CN (1) CN115038461A (es)
AR (1) AR121066A1 (es)
AU (1) AU2021208493B2 (es)
BR (1) BR112022013720A2 (es)
CA (1) CA3168108A1 (es)
IL (1) IL294445B2 (es)
MX (1) MX2022008830A (es)
TW (1) TW202140521A (es)
WO (1) WO2021144369A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
US20220202923A1 (en) * 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
WO2023111907A1 (en) * 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
JP5019494B2 (ja) 1997-04-01 2012-09-05 コリクサ コーポレーション モノホスホリルリピドａの水性免疫アジュバント組成物
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
WO2001025254A2 (en) 1999-10-04 2001-04-12 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
EP1385541B1 (en) 2000-04-13 2008-06-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
WO2002004496A2 (en) 2000-07-07 2002-01-17 Medimmune, Inc. Fimh adhesin proteins and methods of use
CA2420234A1 (en) 2000-08-18 2002-02-28 Medimmune, Inc. Method of administering fimh protein as a vaccine for urinary tract infections
AU2001297896A1 (en) 2000-12-08 2003-01-02 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
AU2006245969B8 (en) 2005-05-11 2011-08-25 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
US8895014B2 (en) 2008-02-20 2014-11-25 Glycovaxyn Ag Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
AP2015008700A0 (en) 2013-05-18 2015-08-31 Univ California Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) * 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
LT3110441T (lt) 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
US10722580B2 (en) 2015-05-13 2020-07-28 University Of Washington Compositions and methods for treatment and prevention of uropathogenic E. coli infection
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof

Also Published As

Publication number Publication date
US20230049056A1 (en) 2023-02-16
US11421003B2 (en) 2022-08-23
TW202140521A (zh) 2021-11-01
JP7485771B2 (ja) 2024-05-16
IL294445B1 (en) 2023-06-01
US20210221856A1 (en) 2021-07-22
CN115038461A (zh) 2022-09-09
JP2024045126A (ja) 2024-04-02
KR20220128372A (ko) 2022-09-20
IL294445A (en) 2022-09-01
US12012435B2 (en) 2024-06-18
CA3168108A1 (en) 2021-07-22
BR112022013720A2 (pt) 2022-10-11
WO2021144369A1 (en) 2021-07-22
JP2023500749A (ja) 2023-01-10
AU2021208493A1 (en) 2022-06-30
EP4090363A1 (en) 2022-11-23
AU2021208493B2 (en) 2023-03-30
IL294445B2 (en) 2023-10-01
MX2022008830A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
AR121066A1 (es) Mutante de fimh, composiciones que lo contienen y uso del mismo
CL2019002134A1 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas.
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR114445A1 (es) Conjugados de il-15, y sus usos
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
BR122020006918B8 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
BR112017017894A2 (pt) composições de alérgenos misturados e métodos para usar as mesmas
PH12020550051A1 (en) Glp-1 compositions and uses thereof
BR112015023105A8 (pt) construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo.
MY166228A (en) Compositions comprising mixtures of semifluorinated alkanes
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
IN2014CN04187A (es)
BR112021006598A2 (pt) composição farmacêutica líquida, e, kit
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
AR124604A1 (es) Mutantes de fimh, composiciones con los mismos y uso de los mismos
CO2020010193A2 (es) Una composición farmacéutica para la anemia
PE20151978A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo
CL2022000774A1 (es) Vacunas para vhb y métodos de tratamiento de vhb
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
PE20151866A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades estimulantes de adiponectina y usos del mismo
AR108631A1 (es) Formulación de neurotoxinas
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22